[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638901":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":28,"locations":34,"responsibleParty":54,"collaborators":10,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":76,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University Hospital, Clermont-Ferrand","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Anti-IL-6 group",null,"Patient on anti-IL-6 therapy",[13,14],"Other: Migraine assessement","Other: Patient Global Impression of Change",{"label":16,"type":10,"description":17,"interventionNames":18},"Anti-TNF group","Patients on anti-TNF therapy",[13,14],[20,24],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"Migraine assessement","Migraine frequency and intensity will be assessed in patients on anti-IL-6 (anti-IL-6 group) and anti-TNF (anti-TNF group).",[9,16],{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"Patient Global Impression of Change","Migraine frequency and intensity will be assessed in patients taking anti-IL-6 (anti-IL-6 group) and anti-TNF therapy (anti-TNF group) using the Patient Global Impression of Change (PGI-C) score.",[9,16],[29],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"Lise Laclautre","CONTACT","0473754963","promo_interne_drci@chu-clermontferrand.fr",[35],{"facility":36,"status":10,"city":37,"state":10,"zip":10,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Chu Clermont-Ferrand","Clermont-Ferrand","France","FR",{"type":41,"coordinates":42},"Point",[43,44],3.08682,45.77969,{"lat":44,"lon":43},[47,48,51],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},{"name":49,"role":50,"phone":10,"phoneExt":10,"email":10},"Sylvain MATHIEU","PRINCIPAL_INVESTIGATOR",{"name":52,"role":53,"phone":10,"phoneExt":10,"email":10},"Emily STUCHFIELD-DENBY","SUB_INVESTIGATOR",{"type":55,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100638901","efficacy-of-anti-il-6-treatments-on-migraine-in-patients-treated-with-anti-il-6-for-a-rheumatological-condition-100638901",false,"NCT07598045","Efficacy of Anti-IL-6 Treatments on Migraine in Patients Treated With Anti-IL-6 for a Rheumatological Condition","RHUMIL-6","Inclusion Criteria (for screening) :\n\n* at least 18 years old\n* ongoing or previous anti-IL-6 (anti-IL-6 group) or anti-TNF (anti-TNF group) therapy, taken for at least 3 months\n\nInclusion Criteria (patients to be enrolled) : migrainous patients, identified using the International Classification of Headache Disorders, version 3 (ICHD-3) criteria from the International Headache Society (IHS) during the telephone call\n\nExclusion Criteria:\n\n* Biotherapy treatment in the context of a diagnosis of giant cell arteritis\n* Verbal communication not possible\n* No affiliation to the French national health insurance system, legal protection measure (guardianship, curatorship, judicial protection)","ALL","18 Years",{"count":66,"type":67},320,"ESTIMATED","OBSERVATIONAL","Migraine affects approximately 15% of the global population. Its prevalence doubles or even triples in individuals with chronic inflammatory conditions, such as chronic inflammatory rheumatic diseases (34%), multiple sclerosis (MS) (46%), or endometriosis (35%). The prevalence of chronic migraine - defined as at least 15 headache days per month (on average over the past 3 months), of which at least 8 days have migrainous features - is also higher in certain conditions such as MS (4%) compared to the general population (1%). The mechanisms underlying migraine and its chronification remain uncertain, but inflammation appears to play an important role in its pathophysiology: it is present from the onset of a migraine attack, represented by the release of pro-inflammatory cytokines that sensitize the trigeminal system and promote the occurrence of new attacks. The investigators' recent bibliographic work has demonstrated elevated levels of interleukin-6 (IL-6), a pro-inflammatory cytokine, in the blood of episodic migraine patients between attacks (migrainous status) compared to non-migrainous subjects, and in chronic migraine patients compared to episodic migraine patients (chronic migraine status). IL-6 appears to play a role in the pathophysiology of migraine, and elevated levels may represent a marker of poorer response to prophylactic treatments. IL-6 levels are also elevated in inflammatory rheumatic diseases and are associated with disease severity. The efficacy of IL-6 pathway-blocking treatments in inflammatory rheumatic diseases is now well established, and these agents are commonly used for this indication. IL-6 could therefore represent a shared pathophysiological link between migraine and inflammatory rheumatic diseases. However, no study to date has measured the effect of IL-6-blocking treatments on migraine. This study therefore aims to assess the effect of anti-IL-6 treatments on migraine in migrainous patients followed in the rheumatology department of the Clermont-Ferrand University Hospital and treated with anti-IL-6 therapy for their rheumatological condition (rheumatoid arthritis, polymyalgia rheumatica, etc.). It will provide preliminary results regarding the effect of anti-IL-6 agents on migraine and could justify future therapeutic studies.",[71],"Migraine",[71,73,74,75],"Inflammation","Anti-IL-6 therapy","Chronic inflammatory rheumatic diseases","NOT_YET_RECRUITING","2026-06-02",{"date":79,"type":80},"2026-06-04","ACTUAL",{"date":82,"type":67},"2026-05-26",{"date":84,"type":67},"2027-05-26",{"name":5,"class":6},1]